Pfizer

Given the muted response to the deal on Monday, analysts seem skeptical that this will be as easy as Pfizer makes it sound

Pfizer will spend USD 43 billion to buy Seagen and deepen its reach into treating cancer. The pharmaceutical giant said Monday that it will pay USD 229 per Seagen share. Together, Pfizer and Seagen seek to accelerate the next generation of cancer breakthroughs and bring new solutions to patients by combining the power of Seagen's antibody-drug conjugate (ADC) technology with the scale and strength of Pfizer's capabilities and expertise," Pfizer Chairman and CEO Dr. Albert Bourla said in a statement. Bothell, Washington-based Seagen Inc. is a biotech drug developer. Its key products use monoclonal antibodies that bind to the surface of a tumour cell to deliver a cancer-killing agent while sparing surrounding healthy tissue. Monoclonal antibodies are lab-made proteins delivered mostly by IV at an infusion center, according to the Cleveland Clinic. Seagen's top seller, Adcetris, treats lymph system cancers. It brought in USD 839 million in sales last year, a 19 per cent increase over

Deal will help the firm add to its line-up of cancer treatments

The Delhi High Court has directed a firm to pay Rs 2 crore as damages to pharma giant Pfizer Inc for committing wilful" and "contumacious contempt of court by disobeying its order. The court said if the director of the firm, Triveni Interchem Pvt Ltd, fails to pay the amount in two weeks, he shall be taken into custody and detained in a civil prison for two weeks at Tihar jail here. The court, in an interim order, had restrained the firm from making, selling, distributing, advertising, exporting or importing or dealing with any product having compound Palbociclib' or any pharmaceutically acceptable salt as it would infringe the patent of plaintiff Pfizer. As the firm was found continuing to sell Palbociclib, the court held the defendants guilty of wilful disobedience of its order and committing contempt of court. In these circumstances, as the defendants were completely unwilling to acknowledge the fact that it was selling Palbociclib, the court was constrained to hold the defendan

Pfizer Inc. and its group companies had filed a suit in the court against Triveni Interchem Private Limited & others accusing the for infringing their patent(IN 218291) for the compound Palbociclib

Pfizer surprised Wall Street with a prediction for a bigger-than-expected sales drop this year for two key products: its COVID-19 vaccine and treatment. The drugmaker also released an earnings forecast that is below analyst expectations, sending shares lower before the opening bell Tuesday. Pfizer expects sales of both the vaccine Comirnaty and the treatment Paxlovid to tumble next year before starting to rebound. That drop was expected as the drugmaker shifts from supplying government contracts to sales on the commercial market in the United States. But Pfizer said Tuesday that it expects Comirnaty sales to tumble 64% to about $13.5 billion this year. It predicts a 58% drop for Paxlovid to about $8 billion. Wall Street expects more than $14 billion in sales from Comirnaty and another $10.5 billion from Paxlovid, according to FactSet. Overall, Pfizer predicts that adjusted earnings will range between $3.25 and $3.45 per share in the new year. Analysts forecast earnings of $4.34

Protectionism as a result of fear meant the governments closed down borders, making it difficult to export vaccines, says Albert Bourla, Pfizer's chief executive officer

The potential risk with Pfizer's vaccine was not seen in other safety databases, nor was it seen with Moderna Inc.'s Covid vaccine, the officials said in a statement

Bourla said the company had shipped thousands of courses of the treatment in 2022 to China and in the past couple of weeks, had increased that to millions

Pfizer and the government agency that oversees the state medical insurance program failed to agree on a further cut on the price of Paxlovid

The policy that came into effect on January 1, 2023, gives biological and adoptive fathers the option to take leaves in up to four tranches

Beijing will begin distributing Pfizers Covid 19 drug Paxlovid to the citys community health centres in the coming days, state media reported on Monday

Glenmark Pharmaceuticals on Tuesday said it has entered into a settlement agreement with Pfizer Inc regarding a cancer treatment drug. The Mumbai-based drug maker and its US-based unit have inked a settlement pact with drug major Pfizer Inc for Axitinib Tablets (1 mg and 5 mg). Glenmark's product is the generic version of Pfizer's Inlyta tablets, used to treat kidney cancer. According to IQVIATM sales data for the 12-month period ending September 2022, the Inlyta tablets (1 mg and 5 mg) achieved annual sales of around USD 644.5 million. Glenmark said its current portfolio consists of 177 products authorised for distribution in the US marketplace and 47 abbreviated new drug applications (ANDA's) are pending for approval with the US Food and Drug Administration. Shares of of the drug maker were trading 1.54 per cent up at Rs 417.9 apiece on BSE.

Other companies have paused advertising on the platform, including General Motors, Volkswagen, Pfizer and General Mills.

Its cost of materials consumed fell 2.1% to Rs 94.4 crore, accounting for about 21% of total expenses in the quarter

The research, based on an analysis of electronic health records in databases maintained by the Department of Veterans Affairs, suggests that wider use of Paxlovid won't just stave off critical disease

The single-dose vaccine candidate is a combination of Pfizer's mRNA-based flu shot and the companies' Omicron-tailored Covid-19 booster shot

Pfizer will charge USD 110 to USD 130 for a dose of its COVID-19 vaccine once the U.S. government stops buying the shots, but the drugmaker says it expects many people will continue receiving it for free. Pfizer executives said the commercial pricing for adult doses could start early next year, depending on when the government phases out its program of buying and distributing the shots. The drugmaker said it expects that people with private health insurance or coverage through public programs like Medicare or Medicaid will pay nothing. The Affordable Care Act requires insurers to cover many recommended vaccines without charging any out-of-pocket expenses. A spokesman said the company also has an income-based assistance program that helps eligible U.S. residents with no insurance get the shots. The price would make the two-dose vaccine more expensive for cash-paying customers than annual flu shots. Those can range in price from around $50 to $95, depending on the type, according to

Outside the United States, Pfizer said it already has contracts with governments in many developed markets that extend through 2023 with prices that have already been set

Their rise and subsequent slump were sharper than the other 131 members of the Bloomberg Billionaires Index whose net worth more than doubled, but wasn't as reliant on how Covid altered lives